SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc.

NEW YORK, May 30, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors in Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investors are encouraged to contact Danielle Peyton at (email protected) or 646-581-9980, extension 7980.

The investigation concerns whether Regeneron and certain of its officers and/or directors engaged in securities transactions. Fraud or other unlawful business practices.

(Click here for information on joining the class action lawsuit.)

At 10 April 2024The U.S. Department of Justice (“DOJ”) issued a press release announcing that it had filed a lawsuit against Regeneron under the False Claims Act. The lawsuit alleges that the company failed to report millions of dollars in rebates to drug distributors. As a result, the DOJ claims that the average selling price of Regeneron’s drug Eylea was increased beyond the amount approved by Medicare.

Following this news, Regeneron’s share price fell 31,50 € per share or around 3.36% over two trading sessions and closed at $904.70 At 12 April 2024.

Pomerantz LLP, with offices in new York, Chicago, Los Angeles, London, ParisAnd Tel-Avivis considered one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. PomerantzKnown as the dean of class action lawyers, Pomerantz was a pioneer in the field of securities class action litigation. Today, more than 85 years later, Pomerantz continues the tradition he established and fights for the rights of victims of securities class action litigation. FraudBreach of fiduciary duty and corporate misconduct. The firm has won billions of dollars in damages on behalf of class action plaintiffs. See www.pomlaw.com.

Attorney advertising. Past results do not guarantee similar results.

CONTACT:
Danielle Peyton
Pomerantz LLP
(email protected)
646-581-9980 extension 7980

Never miss a story from Pomerantz LLP again.